Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy. Patients participated in randomized comparisons of (1) doxorubicin given with or without dexrazoxane...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Moghrabi, Albert, Levy, Donna E., Asselin, Barbara, Barr, Ronald, Clavell, Luis, Hurwitz, Craig, Samson, Yvan, Schorin, Marshall, Dalton, Virginia K., Lipshultz, Steven E., Neuberg, Donna S., Gelber, Richard D., Cohen, Harvey J., Sallan, Stephen E., Silverman, Lewis B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2007
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785142/
https://ncbi.nlm.nih.gov/pubmed/17003366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-027714
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia